Back to top
more

Urogen Pharma (URGN)

(Real Time Quote from BATS)

$14.32 USD

14.32
2,035

+0.17 (1.20%)

Updated Apr 29, 2024 10:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.46% and 5.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 4.92% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why

by Zacks Equity Research

This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the candidate is expected next year.

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at an 89.6% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of 8.85% and 6.23%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -10.29% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of 6.47% and 3.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 2.70% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline

by Zacks Equity Research

Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.28% and 48.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of -8.47% and 13.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of 7.38% and 20.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) Moves 10.3% Higher: Will This Strength Last?

by Zacks Equity Research

Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of 11.28% and 2.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Axsome Therapeutics (AXSM) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 10.92% and 8.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 0% and 269.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of 8.09% and 13.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -19.40% and 6.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.63% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 55.17% and 3.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?